Published in Pharma Law Weekly, August 22nd, 2006
This patent protects, apart from the composition of a group of DHODH inhibitors that are chemically related to 4SC's clinical drug candidate (SC12267), also their use as a medication to treat diseases, such as rheumatoid arthritis or cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.